Veracyte (VCYT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.80 (+1.87%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Veracyte (VCYT)
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.

Key Insights

Critical company metrics and information
  • Share Price

    $43.58
  • Market Cap

    $3.38 Billion
  • Total Outstanding Shares

    77.50 Million Shares
  • Total Employees

    815
  • Dividend

    No dividend
  • IPO Date

    October 30, 2013
  • SIC Description

    Services-medical Laboratories
  • Homepage

    https://www.veracyte.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$66.12 Million
Net Cash Flow From Financing Activities, Continuing$10.06 Million
Net Cash Flow, Continuing$71.55 Million
Net Cash Flow From Investing Activities, Continuing$-4.63 Million
Net Cash Flow From Financing Activities$10.06 Million
Net Cash Flow From Operating Activities$66.12 Million
Net Cash Flow From Investing Activities$-4.63 Million
Exchange Gains/Losses$274,000.00
Net Cash Flow$71.83 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$-9.27 Million
Net Income/Loss Attributable To Parent$-9.27 Million
Income/Loss From Continuing Operations Before Tax$-8.17 Million
Operating Expenses$439.09 Million
Benefits Costs and Expenses$433.50 Million
Operating Income/Loss$-23.54 Million
Net Income/Loss Available To Common Stockholders, Basic$-9.27 Million
Net Income/Loss$-9.27 Million
Research and Development$68.68 Million
Basic Earnings Per Share$-0.13
Revenues$425.33 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Average Shares$77.50 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Average Shares$76.26 Million
Diluted Earnings Per Share$-0.13
Preferred Stock Dividends And Other Adjustments$0.00
Costs And Expenses$439.09 Million
Other Operating Expenses$370.41 Million
Income Tax Expense/Benefit$1.10 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$356.85 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity$1.18 Billion
Intangible Assets$108.87 Million
Noncurrent Liabilities$28.67 Million
Assets$1.28 Billion
Inventory$20.36 Million
Other Non-current Assets$809.29 Million
Equity Attributable To Parent$1.18 Billion
Liabilities$98.98 Million
Current Liabilities$70.31 Million
Noncurrent Assets$918.17 Million
Wages$30.74 Million
Other Current Liabilities$29.90 Million
Accounts Payable$9.67 Million
Other Current Assets$336.49 Million
Liabilities And Equity$1.28 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Veracyte (VCYT)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.